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a b s t r a c t
A murine IgG mAb, WR321, selected for the ability to bind to phosphatidylinositol-4-phosphate and
phosphatidylinositol-4,5-bisphosphate, but an inability to bind to any of 17 other lipids, including phos-
phatidylinositol, was examined as a probe for studying interactions of HIV-1 with primary human periph-
eral blood mononuclear cells. The WR321 mAb broadly neutralized CCR5-tropic strains of HIV-1 to
prevent infection of the cells. The mAb also exhibited direct interaction with cells in the culture, resulting
in secretion of chemokines that interfered with the interaction of HIV-1 virions with CCR5, the coreceptor
for HIV-1 on the susceptible cells, leading to inhibition of infection by HIV-1. Phosphoinositides that are
recognized by WR321 do not exist on the external surface of cells, but are concentrated on the inner sur-
face (cytoplasmic leaflet) of the plasma membrane. Murine anti-phosphoinositide mAbs similar to
WR321 have previously been directly microinjected into a variety of cultured cells, resulting in important
changes in the functions of the cells. The present results suggest that binding of a mAb to phosphoinosi-
tides, resulting in secretion of b-chemokines into the culture medium and neutralization of infection by
CCR5-tropic HIV-1 of nearby susceptible cells, occurred by uptake and binding of the mAb at an intracel-
lular location in the cultured cells that then led to secretion of HIV-1-inhibitory b-chemokines.
Published by Elsevier Inc.
1. Introduction
Antibody-based approaches to studies of the immunobiology of
HIV-1, and to development of vaccines to HIV-1/AIDS, often rely on
antibody-mediated inhibition (neutralization) of infection of sus-
ceptible cells. One such assay utilizes human peripheral blood
mononuclear cells (PBMC) as targets for infection by HIV-1 [1]. In
the course of examining the effects of monoclonal antibodies
(mAbs) in the PBMC assay, we discovered that two murine IgM
mAbs (PIP1 and PIP4, now known asWR301 andWR304) that were
initially selected for the ability to bind to phosphatidylinositol-4-
phosphate (PIP), each neutralized HIV-1 [2,3]. In addition, we dis-
covered that an important, but rare, broadly neutralizing human
IgG mAb, known as 4E10, that had previously been reported to
bind simultaneously both to a linear site on the membrane proxi-
mal external region (mper) of gp41 from HIV-1 and to cardiolipin
(diphosphatidylglycerol), also bound to PIP [2,4]. Despite the lipid
binding similarities between 4E10 and WR304, it was subse-
quently found that each mAb also bound to a wide variety of other
types of lipids, including phosphatidylinositol-4,5-bisphosphate
(PIP2) and many other phospholipids, cholesterol, glycolipids
(4E10, but not WR304, bound to glucosyl ceramide and galactosyl
ceramide), a sulfated glycolipid (sulfogalactosyl ceramide, also
known as sulfatide), and even a glycophospholipid (lipid A, the li-
pid moiety of lipopolysaccharide that covers the surface of Gram
negative bacteria) [5].
Phosphoinositides comprise a group of seven intracellular
phospholipid species that are reversibly generated by phosphory-
lation of the precursor molecule, phosphatidylinositol (PI), at posi-
tions 3,4, and 5 of the inositol ring [6]. Although PIP and PIP2 occur
on plasma membranes of cells, and although PIP2 may constitute
as much as 5% or more of the total lipids of plasma membranes,
all of the phosphoinositides are thought to occur exclusively on
the inner (cytoplasmic) leaflets of plasmamembranes and on intra-
cellular organelles where they serve as intermediates in numerous
types of intracellular signaling events [6]. Despite the absence of
phosphoinositides on cell surfaces, they still remained as candi-
dates for binding of the WR304 and 4E10 mAbs to HIV-1 because
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phosphoinositides are known to be important chemical constitu-
ents of HIV-1 virions [7]. This is because phosphoinositides are
functionally active both during the intracellular assembly of viri-
ons in host cells and localization of gag to the plasma membrane
whereby PIP2 serves as a bridge between the matrix protein and
the envelope of HIV-1 [8–11]. It was thus concluded that although
both 4E10 and WR304 could neutralize HIV-1 in the PBMC assay
without binding to any HIV-1 proteins, it seemed likely that the
mAbs could bind to one or more HIV-1 lipids, even if the exact lipid
binding sites, whether phosphoinositides or other lipids, remained
unclear because of very broad lipid binding specificities of the
mAbs.
Recently, a novel alternative neutralizing mechanism for anti-
lipid mAbs has been proposed that does not require any direct
binding of the anti-phospholipid antibodies to HIV-1. A neutraliz-
ing human mAb, CL1, was described as having binding capabilities
for both cardiolipin and phosphatidylserine, but no binding to
HIV-1 envelope protein, and it inhibited proliferation of CCR5-tro-
pic, but not CXCR4-tropic HIV-1 strains in a PBMC assay [12]. In
this case, release of several b-chemokines, including MIP-1a and
MIP-1b, was observed in the PBMC culture fluid. b-Chemokines
are believed to be effectors secreted by many cells, including
CD4+ and CD8+ lymphocytes, NK cells, and monocytes in the PBMC
that inhibit infection by binding to CCR5, thus blocking infection
with HIV-1 strains that utilize CCR5, but not those that utilize
CXCR4, as a co-receptor [13]. Based on binding of CL1 to cells in
the PBMC culture, it was hypothesized that CL1 bound to plasma
membrane phospholipid(s) and caused secretion of b-chemokines
that interfered with binding of HIV-1 to CCR5-dependent, but not
to CXCR4-dependent, viruses [12]. In the present study, we explore
further the lipid binding specificities of CL1, including binding to
phosphoinositides, and we describe a new murine neutralizing
IgG mAb (WR321) which binds only to phosphoinositides PIP and
PIP2 among 19 lipids tested, but which also causes release of
HIV-1-inhibitory b-chemokines by PBMC even in the absence of
HIV-1.
2. Materials and methods
2.1. Lipids, liposomes, proteins, and peptides
Recombinant, truncated HIV-1 gp41 (HXB2) (Swiss-Prot Acces-
sion Number P04578) containing amino acids 541–682 with 6 His
attached to the carboxy terminus and expressed Pichia pastoris,
was purchased from The Biotech Source (Franklin, MA). Mper23,
LELDKWASLWNWFDITNWLWYIK, was synthesized in-house using
FMOC chemistry and standard solid-phase techniques with free
amino termini [14]. Lipids and lipid antigens were obtained as
described before [5]. Multilamellar liposomes containing
DMPC:Chol:PIP (1:1.5:1) were prepared at a concentration of
50 mM phospholipid containing lipid A and mper23 at 200 lg/ml
[3,15].
2.2. Monoclonal antibodies
Female BALB/c mice (Jackson Laboratories, Bar Harbor, ME)
were immunized intraperitoneally 6 times with 0.1 ml of lipo-
somes at 3 week intervals. Three weeks after the last immuniza-
tion, a mouse was boosted by the intravenous route and the
spleen was removed 4 days after boosting. The spleen cells were
fused with SP2/0 cells obtained from the American Type Culture
Collection (ATCC), Chantilly, VA, and hybridomas were cloned
using ClonaCell-HY Hybridoma Kit (Stemcell Technologies, (Van-
couver, BC, Canada). WR321 was grown in serum-free media
(Invitrogen, Carlsbad, CA), and purified using a protein G kit. The
isotype of WR321 was determined as IgG2b with a kappa light
chain using an isotype kit (Roche, Diagnostics Corp., Indianapolis,
IN). TFTB-1 cells, which secrete a mouse IgG to the ricin B chain,
were purchased from ATCC, and the mAb was grown and purified
as described above. The human lgG anti-phospholipid mAb CL1
was kindly supplied as a gift by Drs. Pojen Chen (UCLA) and Barton
Haynes (Duke University). Each of the WR321 and CL1 mAbs had
very low levels of endotoxin.
2.3. ELISA
Individual lipids as indicated, gp41, and mper23 peptide, were
each used as capture antigens, and assays using the antigens were
performed as described for mouse antibodies [3] and human anti-
bodies [5]. Assay background was determined by using wells lack-
ing antigen, and values less than twice the background are
considered negative. Values greater than twice background are
indicated by asterisks in Fig. 1. Cell culture supernatant chemo-
kines, MIP-1a, MIP-1b, and Rantes, and interferon-c were quanti-
fied with ELISA kits (R&D Systems, Minneapolis, MN).
2.4. HIV-1 neutralization assay
PBMC neutralization assays were performed as previously de-
scribed with replication component, Renila reniformis luciferase
Fig. 1. Lipid binding specificity of WR321 and CL1 as measured by ELISA. Data are
triplicate determination ± standard deviation of a representative assay which was
repeated 3 times. Values are the absorbance of the binding seen from 100 ng of mAb
to 1 nmol of coating lipid. Data have the background from wells lacking mAb
subtracted. Bars with asterisks represent absorbances that were >twice background
and represented positive binding. Abbreviations used were phosphatidylinositiol-4-
phosphate (PIP), phosphatidylinositol-4,5-phosphate3 (PIP2), phosphatidylinositol
(PI), dimyristoyl phosphatidic acid (DMPA), dimyristoyl phosphatidylglycerol
(DMPG), cardiolipin (CL), dimyristoyl phosphatidylserine (DMPS), dimyristoyl
phosphatidylethanolamine (DMPE), phosphatidylcholine isolated from eggs (Egg
PC), sphingomyelin (SM), cholesterol (Chol), galactosylceramide (GalCer), glycosyl-
ceramide (GluCer), lactosylceramide (LacCer), ceramide trihexoside (CTH), GM3,
GM1, sulfogalactosylceramide (sulfatide).
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(LucR)-expressing HIV-1 reporter virus NL-LucR [3,16]. The clade B
viruses, Bal and SF162, in T2A-ENV.ectoviruses were kindly pro-
vided by Christiana Ochsenbauer and John Kappes, University of
Alabama at Birmingham. Viral envelope sequences from CRF01_AE
CM235 and Clade C 16–29 were also cloned into LucR. T2A and are
designated 01-pCM235-2-LucR. T2A (CM235) and C-ETH2220-llB-
LucR (16–29), respectively [17].
3. Results
3.1. Binding specificities of WR321 and CL1 to lipids
Representative experiments showing the relative binding of
WR321 and CL1 to 19 different lipids as determined by ELISA is
shown in Fig. 1. CL1 bound to 7 of the 10 phospholipids (PIP,
PIP2, PI, PA, PG, CL, and PS); to cholesterol; to a sulfoglycolipid (sul-
fatide), but not to any other glycolipid; and it bound to lipid A. In
contrast, WR321 bound only to PIP and to a lesser degree to
PIP2. Neither of the mAbs bound to gp41 from HIV-1 or the mper
peptide derived from gp41 (data not shown). These data confirm
the anti-CL and anti-PS binding properties of CL1 [12], but also
demonstrate that the lipid binding specificity of CL1 is relatively
broad and is similar to the relatively broad lipid binding specifici-
ties of the previously reported murine mAbWR304 [5]. In contrast,
we conclude that phosphoinositides represent the dominant, and
probably the sole lipid binding specificities, of WR321.
3.2. Neutralization of HIV-1 by WR321 and CL1 for prevention of
infection of PBMC
The potent broad neutralization properties of CL1 reported by
Moody et al. [12] were confirmed with four different HIV-1 viruses
in four representative experiments with four different PBMC do-
nors (Fig. 2A–D). Similarly, WR321 also exhibited neutralization
with each virus, but the neutralizing titers were lower than those
of CL1. The relative potencies of WR321 and CL1 for 50% neutral-
ization (IC50) of each of the viruses derived from 2 to 4 experiments
is shown in Table 1. The negative control murine IgG mAb, TFTB,
failed to exhibit significant neutralization.
3.3. Chemokine secretion elicited from PBMC by WR321 and CL1
As shown in Fig. 3, with two different PBMC donors, WR321 and
CL1 each caused considerable secretion of the b-chemokines MIP-
la and MIP-lb. As indicated, the secretion by PBMC induced by
WR321 occurred either in the presence or absence of HIV-1. The
secretion of both of these cytokines by PBMC in the presence of
WR321, as shown in Fig. 3, suggests that the secretion of the
b-chemokines was partly, or possibly even completely, due to
binding of the both the CL1 and WR321 mAbs to phosphoinosi-
tides. The data thus further suggest that phosphoinositides on (or
in) the PBMC may be readily available for binding of antibodies
that are highly specific for phosphoinositides.
4. Discussion
The murine mAbs WR301 and WR304 were originally created
after immunization with liposomes containing PIP and lipid A, and
the mAbs were then selected for binding and complement-depen-
dent damage to liposomes containing PIP but not to liposomes lack-
ing PIP [18]. This general method has also been employed by others
for producing and/or selecting mAbs to phosphoinositides [19,20].
However, it is now apparent that considerable unexpected cross-
reactivity of antibodies produced by this method can occur with
other lipids [5,21]. Despite this, the observations in thepresentwork
of the lack of cross-reactivity of WR321 with other lipids, or with
peptide or protein, and previous observations with similar anti-
phosphoinositide mAbs [22], demonstrate that exquisite specifici-
ties of murine mAbs for phosphoinositides can be achieved. The
present work further demonstrates that this can occur even when
the liposomes used for immunization also contain a peptide antigen
in addition to the phosphoinositide.
Based on the narrow specific binding characteristics of WR321,
it appears reasonable to conclude that all of the observed secretion
of b-chemokines in this study could have occurred in response to
binding of the WR321 to one or more phosphoinositides, including
PIP or PIP2. However, in view of the secretion of b-chemokines
after incubation of intact cells with WR321 in the absence of
HIV-1, this conclusion presents an interesting conundrum because
of the complete absence of phosphoinositides on the outer surface
of plasma membranes of non-permeabilized cells. In view of this,
we propose the hypothesis that WR321 could have entered one
or more of the cell types in the PBMC population, either by endo-
cytosis, pinocytosis, or macropinocytosis, where it then exerted
intracellular binding effects on the inner leaflet of plasma mem-
branes or other intracellular organelles, resulting in the secretion
of b-chemokines.
Fig. 2. Neutralization of HIV-1 by WR321 and CL1. MAbs were mixed with four
different Renila luciferase constructs of HIV-1 and the mixture was added to PHA-
stimulated PMBC. Four days later, virus production was measured. Values shown
are the means ± standard deviation of duplicate samples run by two different
operators from representative experiments (See Table 1 for number of experi-
ments). Dashed lines represent 50% neutralization or 50% enhancement.
Table 1
Neutralization of four different strains of HIV-1.
Virus Mean IC50 (lg/ml) ± SDa
WR321 CL-1 TFTB
SF162 2.05 ± 1.24 (N = 3)* 0.35 ± 0.19 (N = 3) >25 (N = 2)
Bal 3.32 ± 2.27 (N = 4) 0.29 ± 0.10 (N = 3) >25 (N = 3)
16/19 1.79 ± 0.22 (N = 3) 0.24 ± 0.22 (N = 3) >25 (N = 2)
CM235 4.33 ± 1.52 (N = 3) 0.26 ± 0.06 (N = 2) >25 (N = 3)
a IC50 was calculated from the antibody dose response curves as illustrated in
Fig. 2. Assays were conducted in duplicate by two different operators. Values are
mean IC50 of the number of independent experiments indicated.
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The exact intracellular binding site of WR321, if it does occur,
will require further detailed intracellular imaging of the trafficking
pattern of the mAb. Furthermore, PIP and PIP2 represent only two
of the seven intracellular phosphoinositide species, and further
analysis of binding specificities could reveal binding to one or more
of the other phosphoinositide species. However, regardless of
which intracellular phosphoinoside species is involved, this
hypothesis would represent a novel HIV-1 neutralization mecha-
nism by which intracellular binding of ingested antibodies exerts
an extracellular inhibitory effect on HIV-1 infection of nearby cells.
In support of this hypothesis of possible intracellular effects of
WR321 exerted through binding to one or more intracellular mem-
brane phosphoinositides, it is known that phosphoinositides, espe-
cially PIP2 and PIP, are present in relatively high concentrations on
the inner leaflet of the plasma membrane lipid bilayer and on other
intracellular organelles [6]. In addition, mAbs to PIP2 that were di-
rectly microinjected into the cytoplasms of individual non-perme-
abilized cultured cells reportedly bound to intracellular PIP2,
thereby leading to a variety of important physiological effects in
various cells [20,22–26]. Although the exact intracellular traffick-
ing patterns and intracellular binding sites of ingested mAbs to
phosphoinositides are unknown, the previous studies with micro-
injected mAbs to phosphoinositides that were similar to WR321
suggest that such uptake might have important biological effects.
The exact mechanism(s) by which ingestion and intracellular bind-
ing of our anti-PIP mAb might have caused the secretion of b-che-
mokines is also not yet clear. However, we suggest the possibility
that the cytoplasmic uptake of a mAb to phosphoinositides might
have been a threatening event to the cell that could have repre-
sented a unique type of intracellular ‘‘danger signal’’. The secretion
of b-chemokines induced by the mAb might then have been a reac-
tion that was similar to other types of mechanisms linking chemo-
kine secretion to innate and adaptive immunity [27].
It should also be pointed out that plus-strand RNA virus families
(including picornoviruses, coronaviruses, and flaviviruses) are
known to cause remodeling of intracellular organelles of infected
host cells to promote PIP lipid-enriched uncoated membranes that
are essential for viral RNA replication [28]. In view of the present
work, it is theoretically possible that cytoplasmic uptake of anti-
bodies that bind to PIP or other phosphoinositides might also have
an impact on the intracellular replication of plus-strand RNA
viruses.
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